- Home
- RFL vs NRXP Comparison
RFL vs NRXP Comparison
Compare RFL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- NRXP
- Stock Information
- Founded
- RFL 2017
- NRXP 2015
- Country
- RFL United States
- NRXP United States
- Employees
- RFL N/A
- NRXP N/A
- Industry
- RFL Real Estate
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- NRXP Health Care
- Exchange
- RFL Nasdaq
- NRXP Nasdaq
- Market Cap
- RFL 54.4M
- NRXP 58.5M
- IPO Year
- RFL N/A
- NRXP N/A
- Fundamental
- Price
- RFL N/A
- NRXP $3.58
- Analyst Decision
- RFL
- NRXP Strong Buy
- Analyst Count
- RFL 0
- NRXP 5
- Target Price
- RFL N/A
- NRXP $31.40
- AVG Volume (30 Days)
- RFL 175.2K
- NRXP 416.8K
- Earning Date
- RFL 11-05-2025
- NRXP 11-13-2025
- Dividend Yield
- RFL N/A
- NRXP N/A
- EPS Growth
- RFL N/A
- NRXP N/A
- EPS
- RFL N/A
- NRXP N/A
- Revenue
- RFL $732,000.00
- NRXP N/A
- Revenue This Year
- RFL N/A
- NRXP N/A
- Revenue Next Year
- RFL N/A
- NRXP $395.09
- P/E Ratio
- RFL N/A
- NRXP N/A
- Revenue Growth
- RFL 35.56
- NRXP N/A
- 52 Week Low
- RFL $1.28
- NRXP $1.10
- 52 Week High
- RFL $3.19
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- RFL 40.95
- NRXP 67.97
- Support Level
- RFL $1.35
- NRXP $3.19
- Resistance Level
- RFL $1.38
- NRXP $3.84
- Average True Range (ATR)
- RFL 0.09
- NRXP 0.22
- MACD
- RFL 0.00
- NRXP 0.05
- Stochastic Oscillator
- RFL 10.00
- NRXP 70.87
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.